Medication Experiences of People with Parkinson's Disease

Sneha Mantri,¹ Kristin Richards,² Steve Arcona,³ Rahul Sasané³

¹Department of Neurology, Duke University, Durham, NC, USA; ²TxCORE, College of Pharmacy, University of Texas at Austin, TX, USA; ³Cerevel Therapeutics, Cambridge, MA, USA

CONCLUSIONS

- People with PD express considerable frustration with medication regimen frequencies
- The side effect burden of dopaminergic PD medications is substantial
- There is a need for enhanced communication and anticipatory guidance between providers and people with PD regarding PD medication


BACKGROUND

- Medication is an important component of the management of Parkinson's disease (PD)
- Few studies investigate the factors that inform the impact of medications for PD on individuals' lives
- Patient experience data are needed to better understand the perspective of people with PD regarding medications for PD and to improve patient care and outcomes

OBJECTIVE

 To better understand experiences with medications from the perspective of people with PD

RESULTS




Time of first dose (n=196)

DESIGN/METHODS


- This cross-sectional survey was administered to US residents via the Qualtrics online survey platform (December 2022)
- Inclusion: (1) PD diagnosis; (2) history of dopaminergic medication use
- Questions focused on medication initiation, dosage frequency, and side effects
- Descriptive statistics were calculated for all variables

SAMPLE CHARACTERISTICS

- 196 people with PD, 58% male
- Race: 68.4% White; 15.8% Black; 10.7% Hispanic/Latino
- Mean (SD) age: 62.5 (±7.6) years
- Mean (SD) disease duration: 4.7 (±4.3) years
- Self-reported PD severity: 60.2% mildmoderate; 39.8% advanced
- 74.5% taking levodopa, 58.7% taking dopamine agonist
- 62.8% report dyskinesias
- 69.9% report OFF time



 64.3% report they set an alarm to take their first dose in the early morning hours, go back to sleep, and then get up for the day



ACKNOWLEDGMENTS: This study was supported by Cerevel Therapeutics. Layout and editorial assistance was provided under the direction of the authors by MedThink SciCom, with funding from Cerevel Therapeutics.